Patents by Inventor Steven D. Paget

Steven D. Paget has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220064150
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 11180483
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 23, 2021
    Assignee: PTC Therapeutics, Inc.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 10584115
    Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 10, 2020
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Publication number: 20200024260
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 23, 2020
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 10428050
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: October 1, 2019
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 10370371
    Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: August 6, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Wu Du, Ramil Baiazitov, Chang-Sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 9975878
    Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 22, 2018
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Hiroo Koyama, Ramil Baiazitov, Wu Du, Chang-sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko
  • Patent number: 9593108
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: March 14, 2017
    Assignee: PTC Therapeutics, Inc.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
  • Publication number: 20160297798
    Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: October 13, 2016
    Inventors: Hiroo Koyama, Ramil Baiazitov, Wu Du, Chang-sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko
  • Publication number: 20160280685
    Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: September 29, 2016
    Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Publication number: 20160214978
    Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 28, 2016
    Inventors: Wu Du, Ramil Baiazitov, Chang-Sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Publication number: 20150315182
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: November 5, 2015
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Patent number: 8735414
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: May 27, 2014
    Assignee: PTC Therapeutics, Inc.
    Inventors: Malcolm MacCoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Song Xiao Huang, Ramesh Kakarla, Gary Mitchell Karp, William Joseph Lennox, Chunshi Li, Ronggang Liu, Yalei Liu, Christie Morrill, Steven D. Paget, Sean W Smith, James Takasugi, Anthony A. Turpoff, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Publication number: 20120184574
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Application
    Filed: April 5, 2010
    Publication date: July 19, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Song Xiao Huang, Ramesh Kakarla, Gary Mitchell Karp, William Joseph Lennox, Chunshi Li, Ronggang Liu, Yalei Liu, Christie Morrill, Steven D. Paget, Sean W. Smith, James Takasugi, Anthony A. Turpoff, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Publication number: 20120135999
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Application
    Filed: April 5, 2010
    Publication date: May 31, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 6951863
    Abstract: Pyridoarylphenyl oxazolidinone compounds of the formula: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: October 4, 2005
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Steven D. Paget, Michele A. Weidner-Wells, Harvey M. Werblood
  • Patent number: 6770664
    Abstract: Bicyclic heterocyclic substituted phenyl oxazolidinone compounds of the formula: wherein Y is a radical of Formulae II or III: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: August 3, 2004
    Inventors: Steven D. Paget, Dennis J. Hlasta
  • Publication number: 20040067994
    Abstract: Bicyclic heterocyclic substituted phenyl oxazolidinone compounds of the formula: 1
    Type: Application
    Filed: June 9, 2003
    Publication date: April 8, 2004
    Inventors: Steven D. Paget, Dennis J. Hlasta
  • Publication number: 20030176422
    Abstract: Pyridoarylphenyl oxazolidinone compounds of the formula: 1
    Type: Application
    Filed: February 6, 2002
    Publication date: September 18, 2003
    Inventors: Steven D. Paget, Michele A. Weidner-Wells, Harvey M. Werblood
  • Patent number: 6608081
    Abstract: Bicyclic heterocyclic substituted phenyl oxazolidinone compounds of the formula: wherein Y is a radical of Formulae II or III: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: August 19, 2003
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Steven D. Paget, Dennis J. Hlasta